With RediCare Control, patients are transforming their health across the spectrum of metabolic health. They are experiencing clinically significant reductions in weight, HbA1c, blood pressure and improved lipid profiles and PCOS remission. Many type 2 diabetic patients have reduced, and some eliminated their diabetes medications. One study on type 2 diabetic patients saw a 48% normalisation of HbA1c.
RediCare Control is creating a new normal in prescription digital therapeutics for treating cardiometabolic diseases. We envision a new way to treat diseases like type 2 diabetes and heart disease by targeting the causes, not just the effects, using prescription digital therapeutics to deliver personalized lifestyle therapy.
Below is a summary RediCare studies from primary care and corporate setting.